Collaborative Agreements (Tables)

6 Months Ended

Jun. 30, 2012

Lilly Collaboration [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule Of Activity Related To Collaboration

The following is a summary of activity related to our collaboration with Lilly and the location in the consolidated statements of operations (in thousands):

	Classification within Consolidated Statements of Operations	Three Months Ended				Six Months Ended
Activity		June 30, 2012		June 30, 2011		June 30, 2012		June 30, 2011
Royalty revenue	Revenues under collaborative agreements	$	957	$	1,401	$	2,083	$	1,401
Gross margin sharing	Collaborative profit sharing	$	—	$	60,652	$	—	$	120,503
Development expense cost-sharing payments received from Lilly for BYETTA and BYDUREON development expense	Reduction of research and development expense	$	—	$	17,842	$	—	$	35,188
Cost-sharing payments due from Lilly for shared sales force expenses, marketing expenses and other commercial or operational support	Reduction of selling, general and administrative expense	$	—	$	2,300	$	—	$	5,637

Takeda Agreement [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule Of Activity Related To Collaboration

The following is a summary of activity related to the Takeda Agreement and the location in the consolidated statements of operations (in thousands):

	Classification within Consolidated Statements of  Operations	Three Months Ended				Six Months Ended
Activity		June 30, 2012		June 30, 2011		June 30, 2012		June 30, 2011
Amortization of up-front payments	Revenues under collaborative agreements	$	1,875	$	1,875	$	3,750	$	3,750
Cost-sharing payments due from Takeda for shared development expenses	Reduction of research and development expense	$	571	$	1,971	$	1,329	$	6,989